Addis & Hill
NMRA icon

Addis & Hill’s Neumora Therapeutics NMRA Stock Holding History

Addis & Hill’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$278K Hold
163,386
– – 0.15% 28
2026
Q2 		$278K Hold
163,386
– – 0.15% 28
2026
Q1 		$319K Hold
163,386
– – 0.19% 26
2025
Q4 		$292K Hold
163,386
– – 0.18% 26
2025
Q3 		$291K Hold
163,386
– – 0.18% 26
2025
Q2 		$120K Hold
163,386
– – 0.08% 27
2025
Q1 		$163K Hold
163,386
– – 0.11% 28
2024
Q4 		$1.73M Sell
163,386
-136,614
-46% -$1.64M 1.28% 11
2024
Q3 		$3.96M Hold
300,000
– – 3.04% 9
2024
Q2 		$2.94M Sell
300,000
-14,821
-5% -$153K 2.45% 9
2024
Q1 		$4.19M Buy
+314,821
New +$5.09M 3.57% 7

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
MIC Capital Management (UK)
MIC Capital Management (UK) London, United Kingdom $463M AUM 7.9% 1-Year Est. Return
Exor N.V.
Exor N.V. Amsterdam, Netherlands $26.6B AUM 9.51% 1-Year Est. Return
Wellcome Trust
Wellcome Trust London, United Kingdom $9.16B AUM 11.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lunate Capital
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $714M AUM 64.22% 1-Year Est. Return

Addis & Hill's NMRA Position: Q3 2026 in Review

Addis & Hill held its Neumora Therapeutics (NMRA) position steady in Q3 2026 at 163,386 shares worth $278K. The position accounts for 0.15% of the portfolio, ranked #28.

Addis & Hill first reported a position in NMRA in Q1 2024 and has held it in 11 quarters since. The position peaked at $4.19M in Q1 2024. 82 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • Addis & Hill held 163,386 shares of Neumora Therapeutics worth $278K as of Q3 2026.
  • Addis & Hill left its Neumora Therapeutics share count unchanged in Q3 2026.
  • Neumora Therapeutics made up 0.15% of Addis & Hill's portfolio in Q3 2026, its #28 holding.
  • Addis & Hill first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Addis & Hill's Neumora Therapeutics position peaked at $4.19M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Addis & Hill's 13F filing for Q3 2026, filed 19 Oct 2026.